Key result
Glyburide is linked to ~16% fewer kidney complications vs glimepiride and glipizide, despite more severe hypoglycemia.
Why the study?
To assess the within-class variation in kidney outcomes following the initiation of sulfonylurea therapy.
Does the choice of sulfonylurea (glimepiride, glipizide, or glyburide) affect the risk of kidney complications in adults with type 2 diabetes and moderate cardiovascular risk?
Observational (n=295,092)
Does the choice of sulfonylurea (glimepiride, glipizide, or glyburide) affect the risk of kidney complications in adults with type 2 diabetes and moderate cardiovascular risk?
Effect estimate: HR 0.84 (95% CI 0.76 to 0.92)
Absolute Event Rate: 1.8% vs 2.1%
In adults with type 2 diabetes, glyburide initiation was associated with a modestly lower risk of kidney complications compared to glimepiride and glipizide, though with a higher risk of severe hypoglycemia.
No takes yet. Share an insight, caveat, or question.
May not yet inform sulfonylurea selection; hypothesis-generating observational association needing RCT confirmation.
Sklepinski et al. (2026) conducted an observational in Type 2 diabetes at moderate cardiovascular risk (n=295,092). Glyburide vs. Glimepiride and Glipizide was evaluated on Incidence of chronic kidney disease (CKD) stage 3 or worse, including initiation of kidney replacement therapy (HR 0.84, 95% CI 0.76 to 0.92). Glyburide was associated with a lower risk of kidney complications compared with glimepiride (HR 0.84; 95% CI 0.76-0.92) and glipizide (HR 0.81; 95% CI 0.73-0.89), despite higher severe hypoglycemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: